208 related articles for article (PubMed ID: 19127260)
1. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials.
Neoptolemos JP; Stocken DD; Tudur Smith C; Bassi C; Ghaneh P; Owen E; Moore M; Padbury R; Doi R; Smith D; Büchler MW
Br J Cancer; 2009 Jan; 100(2):246-50. PubMed ID: 19127260
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
[TBL] [Abstract][Full Text] [Related]
3. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
[TBL] [Abstract][Full Text] [Related]
4. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
Br J Cancer; 2018 Apr; 118(7):947-954. PubMed ID: 29515256
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant and adjuvant strategies for pancreatic cancer.
Ghaneh P; Smith R; Tudor-Smith C; Raraty M; Neoptolemos JP
Eur J Surg Oncol; 2008 Mar; 34(3):297-305. PubMed ID: 17936564
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.
Carter R; Stocken DD; Ghaneh P; Bramhall SR; Olah A; Kelemen D; Bassi C; Friess H; Dervenis C; Spry N; Büchler MW; Neoptolemos JP;
Int J Cancer; 2009 Jun; 124(12):2960-5. PubMed ID: 19330830
[TBL] [Abstract][Full Text] [Related]
7. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Saif MW
JOP; 2009 Jul; 10(4):373-7. PubMed ID: 19581737
[TBL] [Abstract][Full Text] [Related]
9. ESPAC-1 trial progress report: the European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer.
Neoptolemos JP; Kerr DJ; Beger H; Link K; Pederzoli P; Bassi C; Dervenis C; Fernandez-Cruz L; Laçaine F; Friess H; Büchler M
Digestion; 1997; 58(6):570-7. PubMed ID: 9438604
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of the month. Adjuvant radio-chemotherapy and chemotherapy following curative resection of pancreatic cancer: results of the randomized trial ESPAC-1].
Polus M; Jerusalem G; Sautois B; Silvestre RM; Collette MY; Closon MT; Fillet G
Rev Med Liege; 2002 Feb; 57(2):119-22. PubMed ID: 11942178
[TBL] [Abstract][Full Text] [Related]
11. Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).
Neoptolemos JP; Baker P; Beger H; Link K; Pederzoli P; Bassi C; Dervenis C; Friess H; Büchler M
Int J Pancreatol; 1997 Apr; 21(2):97-104. PubMed ID: 9209950
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
Neoptolemos JP; Dunn JA; Stocken DD; Almond J; Link K; Beger H; Bassi C; Falconi M; Pederzoli P; Dervenis C; Fernandez-Cruz L; Lacaine F; Pap A; Spooner D; Kerr DJ; Friess H; Büchler MW;
Lancet; 2001 Nov; 358(9293):1576-85. PubMed ID: 11716884
[TBL] [Abstract][Full Text] [Related]
13. The case for routine use of adjuvant therapy in pancreatic cancer.
Kennedy EP; Yeo CJ
J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Saif MW
JOP; 2011 Mar; 12(2):106-9. PubMed ID: 21386631
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant regional chemotherapy in advanced pancreatic cancer: results of a prospective study.
Beger HG; Link KH; Gansauge F
Hepatogastroenterology; 1998; 45(21):638-43. PubMed ID: 9684109
[TBL] [Abstract][Full Text] [Related]
16. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.
Bassi C; Stocken DD; Olah A; Friess H; Buckels J; Hickey H; Dervenis C; Dunn JA; Deakin M; Carter R; Ghaneh P; Neoptolemos JP; Buchler MW;
Dig Surg; 2005; 22(5):353-63. PubMed ID: 16293966
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
Morak MJ; van der Gaast A; Incrocci L; van Dekken H; Hermans JJ; Jeekel J; Hop WC; Kazemier G; van Eijck CH
Ann Surg; 2008 Dec; 248(6):1031-41. PubMed ID: 19092348
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for pancreatic cancer.
Sultana A; Cox T; Ghaneh P; Neoptolemos JP
Recent Results Cancer Res; 2012; 196():65-88. PubMed ID: 23129367
[TBL] [Abstract][Full Text] [Related]
19. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
Br J Cancer; 2018 Apr; 118(8):1084-1088. PubMed ID: 29523831
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
Maroun JA; Cripps C; Goel R; Dahrouge S; Boisvert D
Am J Clin Oncol; 1997 Aug; 20(4):387-92. PubMed ID: 9256896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
